Vaccinex, Inc. (VCNX)
- Previous Close
5.89 - Open
6.29 - Bid --
- Ask --
- Day's Range
5.62 - 6.74 - 52 Week Range
4.43 - 100.80 - Volume
12,340 - Avg. Volume
13,722 - Market Cap (intraday)
9.236M - Beta (5Y Monthly) 0.70
- PE Ratio (TTM)
-- - EPS (TTM)
-43.68 - Earnings Date May 13, 2024 - May 17, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead drug candidate, pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D. It is developing Pepinemab, which is in phase 2 study for treatment of Alzheimer's disease and has completed phase 2 study for treatment of Huntington's disease; Pepinemab in combination with Pembrolizumab in phase 2 study for head and neck cancer, Avelumab in phase 2 study for pancreatic cancer, and completed phase 2 study with Avelumab for non-small cell lung cancer; and Pepinemab in combination with Nivolumab completed phase 2 study for melanoma, and trastuzumab and DC vaccine in phase 2 study for breast cancer. The company has also developed ActivMAb, an antibody drug discovery platform based on a novel method for complex targets, such as multi-pass membrane receptors or large and diverse libraries of full-length human monoclonal antibodies on the surface of pox viruses. It has collaborations with Merck Sharp & Dohme; Ares Trading S.A.; The Children's Hospital of Philadelphia; Emory University; Huntington Study Group; H. Lee Moffitt Cancer Center and Research Institute, Inc; Catalent Pharma Solutions, LLC; Surface Oncology, Inc.; and Pharmaceutical and Biotech Co. The company was incorporated in 2001 and is headquartered in Rochester, New York.
www.vaccinex.comRecent News: VCNX
Performance Overview: VCNX
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: VCNX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: VCNX
Valuation Measures
Market Cap
9.24M
Enterprise Value
7.95M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
4.74
Price/Book (mrq)
--
Enterprise Value/Revenue
13.94
Enterprise Value/EBITDA
-0.39
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-246.44%
Return on Equity (ttm)
-1,405.34%
Revenue (ttm)
570k
Net Income Avi to Common (ttm)
-20.25M
Diluted EPS (ttm)
-43.68
Balance Sheet and Cash Flow
Total Cash (mrq)
1.53M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-11.11M